An anxiolytic that suppresses seizures
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Valnoctamide

Item No. 18456

Technical Information
Formal Name
2-ethyl-3-methyl-pentanamide
CAS Number
4171-13-5
Synonyms
  • NSC 32363
  • NSC 34092
  • Valmethamide
  • Valoctamidum
Molecular Formula
C8H17NO
Formula Weight
Purity
≥95%
A crystalline solid
DMF: 16 mg/mlDMSO: 30 mg/mlEthanol: 25 mg/mlPBS (pH 7.2): 1 mg/ml
SMILES
CCC(C(N)=O)C(C)CC
InChi Code
InChI=1S/C8H17NO/c1-4-6(3)7(5-2)8(9)10/h6-7H,4-5H2,1-3H3,(H2,9,10)
InChi Key
QRCJOCOSPZMDJY-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    Valnoctamide is an isomer of the valproic acid amide, valpromide. It has been marketed as an anxiolytic and sedative compound and suppresses neuropathic pain.1,2 Unlike valpromide, valnoctamide is not metabolized to its acid form, valnoctic acid, in vivo and has no teratogenicity.1 It abolishes the activity of myo-inositol-1-phosphate synthase in human brain crude homogenates (Ki = 0.18 mM).3 Valnoctamide suppresses electrographic seizures in animal models of status epilepticus, suggesting potential applications in managing epilepsy.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Rogawski, M.A. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 69(3), 273-294 (2006).

    2. Winkler, I., Blotnik, S., Shimshoni, J., et alEfficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. Br. J. Pharmacol. 146, 198-208 (2005).

    3. Shaltiel, G., Mark, S., Kofman, O., et alEffect of valproate derivatives on human brain myo-inositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing. Pharmacol. Rep. 59(4), 402-407 (2007).

    4. Spampanato, J., and Dudek, F.E. Valnoctamide enhances phasic inhibition: A potential target mechanism for the treatment of benzodiazepine-refractory status epilepticus. Epilepsia 55(9), e94-e98 (2014).